Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JNJ 90301900 (Primary) ; Carboplatin; Durvalumab; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CONVERGE
  • Sponsors Johnson & Johnson Innovation

Most Recent Events

  • 31 Oct 2025 According to a Nanobiotix media release, through the financing agreement with HealthCare Royalty, the Company expects to receive the first potential milestone payments related to clinical development in lung cancer (CONVERGE) by early 2028 subject to closing of the agreement.
  • 21 Jan 2025 According to NANOBIOTIX Media Release, the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial.
  • 11 Dec 2024 Planned initiation date (estimated date of first participant enrollment) changed from 31 Oct 2024 to 20 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top